Q2 2021

Filed Jul 29, 2021 · 10-Q · 29 days after period end · 0001091818-21-000099

Q2 2021 · 10-Q

Revenue—

Net Income

-$122.32K

N/M vs Q2 2020

EPS Diluted

$0.00

— vs Q2 2020

Operating Cash Flowderived-$27,706N/M

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2018
Revenue	—	—	$5.96K	$5.06K
Net Income	-$122.32K	-$126.71K	-$7.18K	-$28.53K
EPS Diluted	$0.00	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioforce Nanosciences Holdings, Inc. · CIK 1310488 · Engraved from SEC EDGAR